Notification of Drug Policy Revisions Effective April 1, 2024 (Posted February 1, 2024) | Providers

Shop Plans

Get Covered
Additional Coverage
Helpful Information
- Find Care
- FAQ
- Blog

Members

Type of Plans
- Medicare
- Health
- Dental
- Vision
Helpful Information
Special Groups

Employers

Get Started
Helpful Information

Agents

Get Started
Help Your Members

Notification of Drug Policy Revisions Effective April 1, 2024 (Posted February 1, 2024)

Medical Drug Policy Name	Revised Criteria
Testosterone Pellet Implantation for Androgen Deficiency Notification	Added requirement for submission of laboratory values for HIV indication with low testosterone levels. Added the following note within policy, “Hormone pellet implantation (e.g., testosterone pellets) is considered investigational for hormone replacement therapy to treat menopause related symptoms. BCBSNC does not provide coverage for investigational services or procedures.”Added requirement for submission of laboratory values for HIV indication with low testosterone levels. Added the following note within policy, “Hormone pellet implantation (e.g., testosterone pellets) is considered investigational for hormone replacement therapy to treat menopause related symptoms. BCBSNC does not provide coverage for investigational services or procedures.” Added requirement for submission of laboratory values for HIV indication with low testosterone levels. Added the following note within policy, “Hormone pellet implantation (e.g., testosterone pellets) is considered investigational for hormone replacement therapy to treat menopause related symptoms. BCBSNC does not provide coverage for investigational services or procedures.” Policy notification given 2/1/2024 for effective date 4/1/2024.

Medical Drug Policy Name

Revised Criteria

Testosterone Pellet Implantation for Androgen Deficiency Notification

Added requirement for submission of laboratory values for HIV indication with low testosterone levels. Added the following note within policy, “Hormone pellet implantation (e.g., testosterone pellets) is considered investigational for hormone replacement therapy to treat menopause related symptoms. BCBSNC does not provide coverage for investigational services or procedures.”Added requirement for submission of laboratory values for HIV indication with low testosterone levels. Added the following note within policy, “Hormone pellet implantation (e.g., testosterone pellets) is considered investigational for hormone replacement therapy to treat menopause related symptoms. BCBSNC does not provide coverage for investigational services or procedures.” Added requirement for submission of laboratory values for HIV indication with low testosterone levels. Added the following note within policy, “Hormone pellet implantation (e.g., testosterone pellets) is considered investigational for hormone replacement therapy to treat menopause related symptoms. BCBSNC does not provide coverage for investigational services or procedures.” Policy notification given 2/1/2024 for effective date 4/1/2024.

Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.

Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語

© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.